High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003–2007
Piotr Kozlowski,
Maria Åström,
Lucia Ahlberg,
Per Bernell,
Erik Hulegårdh,
Hans Hägglund,
Karin Karlsson,
Alicja Markuszewska-Kuczymska,
Beata Tomaszewska-Toporska,
Bengt Smedmyr,
Helene Hallböök
Affiliations
Piotr Kozlowski
1Hematology Section, Department of Medicine, Örebro University Hospital, Örebro
Maria Åström
1Hematology Section, Department of Medicine, Örebro University Hospital, Örebro
Lucia Ahlberg
2Department of Hematology, University Hospital of Linköping, Linköping
Per Bernell
3Karolinska University Hospital, Stockholm
Erik Hulegårdh
4Department of Hematology and Coagulation, Sahlgrenska University, Göteborg
Hans Hägglund
3Karolinska University Hospital, Stockholm
Karin Karlsson
5Department of Hematology, Skåne University Hospital, Lund
Alicja Markuszewska-Kuczymska
6Department of Hematology, Cancer Center, University Hospital, Umeå
Beata Tomaszewska-Toporska
5Department of Hematology, Skåne University Hospital, Lund
Bengt Smedmyr
7Department of Hematology, Uppsala University, Uppsala, Sweden, for the Swedish Adult ALL Group
Helene Hallböök
7Department of Hematology, Uppsala University, Uppsala, Sweden, for the Swedish Adult ALL Group
Background A minority of patients with adult acute lymphoblastic leukemia who relapse are rescued. The aim of this population-based study was to assess the results of reinduction treatment and allogeneic stem cell transplantation in patients in second complete remission.Design and Methods Between 2003–2007, 76 adults (
